| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3293556 | Gastroenterology | 2012 | 18 Pages |
Abstract
Romo1 is a biomarker of HCC progression that might be used in diagnosis. Reagents that inhibit activity of Romo1 and suppress mitochondrial ROS production, rather than eliminate up-regulated intracellular ROS, might be developed as cancer therapies.
Keywords
DPITGF-βRomo1N-acetyl-l-cysteine12-O-tetradecanoylphorbol-13-acetateRT-PCRNACNADPHtPAMMPFITCHCCSmall interfering RNAROSsiRNAtransforming growth factor-βtumor necrosis factor-αLiver cancerPrognostic factorTNF-αfluorescein isothiocyanatematrix metalloproteinaseMetastasisChemotherapy resistancereverse transcription-polymerase chain reactionHepatocellular carcinomareduced nicotinamide adenine dinucleotide phosphateReactive oxygen species
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Jin Sil Chung, SunHoo Park, Seon Ho Park, Eun-Ran Park, Pu-Hyeon Cha, Bu-Yeo Kim, Young Min Chung, Seon Rang Woo, Chul Ju Han, Sang-Bum Kim, Kyung-Suk Suh, Ja-June Jang, Kyoungbun Lee, Dong Wook Choi, Sora Lee, Gi Young Lee, Ki Baik Hahm,